ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Invasive disease-free survival, according to recurrence score and treatment (intention-to-treat population)* in patients with one to three positive axillary lymph nodes

Invasive disease-free survival, according to recurrence score and treatment (intention-to-treat population)* in patients with one to three positive axillary lymph nodes
Recurrence-score category and type of therapy Number of participants Invasive disease-free survival at 5 year
(percent)		 Hazard ratio for recurrence
(95% CI)
Premenopausal women
≤10, endocrine only 174 92.4±2.2 0.47 (0.18-1.20)
≤10, chemoendocrine 151 96.6±1.7  
11 to 15, endocrine only 277 93.3±1.7 0.68 (0.33-1.37)
11 to 15, chemoendocrine 287 95.5±1.4  
16 to 20, endocrine only 254 83.8±2.6 0.57 (0.35-0.94)
16 to 20, chemoendocrine 269 91.5±1.9  
21 to 25, endocrine only 118 85.2±3.6 0.63 (0.30-1.31)
21 to 25, chemoendocrine 121 92.4±2.8  
Women ≤50 years
≤10, endocrine only 145 91.0±2.6 0.31 (0.10-0.94)
≤10, chemoendocrine 135 97.9±1.5  
11 to 15, endocrine only 247 93.1±1.8 0.71 (0.33-1.51)
11 to 15, chemoendocrine 235 95.4±1.6  
16 to 20, endocrine only 227 85.1±2.6 0.58 (0.33-1.00)
16 to 20, chemoendocrine 224 92.2±2.0  
21 to 25, endocrine only 107 80.0±4.3 0.56 (0.27-1.17)
21 to 25, chemoendocrine 98 90.0±3.6  
Postmenopausal women
≤10, endocrine only 434 92.7±1.4 0.72 (0.44-1.18)
≤10, chemoendocrine 434 92.7±1.4  
11 to 15, endocrine only 454 95.8±1.0 1.30 (0.88-1.92)
11 to 15, chemoendocrine 524 93.5±1.2  
16 to 20, endocrine only 525 90.8±1.5 0.91 (0.57-1.43)
16 to 20, chemoendocrine 454 93.2±1.3  
21 to 25, endocrine only 451 93.2±1.3 1.13 (0.75-1.70)
21 to 25, chemoendocrine 255 84.8±2.5  
Women >50 years
≤10, endocrine only 463 93.1±1.3 0.78 (0.48-1.26)
≤10, chemoendocrine 472 95.5±1.0  
11 to 15, endocrine only 554 93.6±1.1 1.22 (0.83-1.79)
11 to 15, chemoendocrine 577 91.2±1.4  
16 to 20, endocrine only 481 92.1±1.3 0.86 (0.56-1.32)
16 to 20, chemoendocrine 496 92.8±1.3  
21 to 25, endocrine only 266 86.9±2.3 1.17 (0.77-1.76)
21 to 25, chemoendocrine 246 81.8±2.7  
IDFS: invasive disease-free survival; SE: standard error.
* Plus–minus values are means ±SE.
¶ A hazard ratio of less than 1 indicates a higher recurrence rate with endocrine therapy only than with chemoendocrine therapy.
From: Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform benefit in node-positive breast cancer. N Engl J Med 2021; 385:2336. Copyright © 2021 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Graphic 134596 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟